Effectiveness of ustekinumab and improvement in real-world work productivity and associated indirect costs in patients with moderate-severe Crohn’s disease in the United States of America
Patients with CD receiving UST had lower mean annual WPL costs and work impairment compared to moderate-to-severe patients with CD not receiving UST along with reduced symptomology over their UST treatment period, suggesting UST offers economic and health related quality of life benefits to this population.
Authors
- Rina Lukanova (ORCID: https://orcid.org/0000-0002-1414-0720)
- Fatima Dawod (ORCID: https://orcid.org/0000-0002-0385-6862)
- J Izanec
- Zhijie Ding
- Sophie Barlow
Institutions
- Janssen (Belgium) (BE)
- Adelphi Group (United Kingdom) (GB)
- Janssen (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1080/03007995.2026.2613549
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00